Johnson & Johnson once again delivered higher-than-expected profits in the first quarter, driven largely by its high-priced cancer drugs and expanding pharmaceutical portfolio — a familiar story in an industry known more for profit margins than affordability.
The company increased its revenue forecast for the year by $700 million, crediting part of the gain to its recent acquisition of the schizophrenia drug Caplyta. Despite the financial boost, J&J kept its profit forecast flat, citing costs from new U.S. tariffs and its $14.6 billion acquisition of biotech firm Intra-Cellular — another costly deal in an industry where consolidation often means fewer choices and higher prices for patients.
This earnings release comes just as U.S. officials are moving to impose stricter trade barriers on countries like China, which supplies a large portion of the active ingredients in American medications. The move, framed as a national security measure, is also raising questions about just how dependent the U.S. has become on foreign manufacturing to fuel domestic drug profits.
Even so, J&J is pressing ahead, now projecting full-year adjusted earnings per share between $10.50 and $10.70, despite estimating around $400 million in additional tariff-related costs — largely absorbed by its medical device division. The company also noted a 25-cent-per-share impact from its Intra-Cellular purchase, suggesting that even multibillion-dollar acquisitions are viewed as manageable bumps in the road when profits are this high.
Some of the tariffs affecting J&J’s supply chain have been temporarily suspended for 90 days, but long-term strategies remain unclear — both for companies and for the patients who ultimately bear the costs of these disruptions.
Shares of the company dipped slightly in premarket trading but remain up nearly 7% on the year. That’s no surprise, considering pharmaceutical stocks have largely been insulated from the latest wave of tariffs, a reminder of how often the industry escapes broader economic pressures that affect others.
Revenue for the quarter climbed to $21.89 billion, a 2.4% increase from last year and ahead of Wall Street estimates. Adjusted earnings hit $2.77 per share — comfortably beating expectations — thanks mostly to continued growth in high-cost prescription drugs.
Pharmaceutical sales came in at $13.87 billion, surpassing forecasts, while medical device revenue rose modestly to $8.02 billion, falling just short of estimates. But with sales and earnings continuing to rise, the real question isn’t how well these companies are doing — it’s at what cost to public health, transparency, and affordability.
This is proof that the pharmaceutical industry isn’t built to cure you — it’s built to keep you dependent. It’s a profit-driven machine that thrives on lifelong customers, not healthy, healed individuals. True healing rarely comes from a pill bottle; it comes from aligning with nature and turning to the remedies God has already provided — herbs, whole foods, rest, sunlight, and a lifestyle rooted in balance. More importantly, lasting wellness begins with the Word of God. When we live by His principles, nourish our bodies with what He created, and put our faith in His promises, we find a kind of healing no corporation can sell. Real health isn’t bought — it’s lived, through the truth of God’s word.
